This was a comment from Smith on Stocks on April 2012 "This indicates that the FDA is going to be satisfied with highly similar products and will not require them to be absolutely identical. Finally, while I have not seen the Teva/ Antares device, others have told me that they are virtually indistinguishable."
Can anybody add what was done to make this vibex pen almost identical to the Epipen? Would a Mother buying this for her child not have a problem using this new generic version? Sorry if this was already adressed on board. I just missed it.
In the form of a letter today from Peter J. Graham. The new guy with ATRS. I wrote every member of the board last a couple weeks ago. Actually a little less then that. I guess getting back to frustrated shareholders is also one of his duties. Thing is I kinda pointed out my displeasure with his predecessor's termination arrangements among other things. I appreciate it!
I sure do nammuang. I guess you like management taking one call on the last CC. You like that? You like management gutting us for bonuses for getting a product through the FDA maze that ATRS isn't even driving? Well?
Really, if you like this stock or industry you are an idiot or not pulling the trigger here. The coding issue will be resolved. Also I would think the physicians get as much or more from private insurance!
Tappy that still doesn't convince me why a LOC would not have been a better play for the shareholders. I don't care how you spin it a LOC at these rates would have possibly been cheaper even if they needed to tap into it. The LOC would not be dilutive if these catalyst come through! Dusa stated it just allows the game to carry on regardless. The only ones it's best for is management. This way they cannot lose either way!
you think DF was the only taker ATRS had for the secondary? Is the best they could do? Why not have done the LOC and not have the dilution, fees or selling pressure from these daily sells?